Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02476708 · ClinicalTrials.gov registry record · NA
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT02476708 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 12 participants.
The verdict
NCT02476708, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cognitive functioning in schizophrenia. Secondary goals are to determine the effect of curcumin over time on negative and positive symptoms, in association with inflammatory markers.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT curcumin 1800mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-02-11 |
| Est. Completion | 2017-08-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02476708
The ClinicalTrials.gov registry entry for NCT02476708 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02476708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02476708 about?
NCT02476708 is a clinical study titled "A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia". This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cogniti...
What is the current status of trial NCT02476708?
This trial is currently terminated. It is a NA study. The enrollment target is 12 participants. The study started on 2016-02-11. Estimated completion is 2017-08-24.
What interventions are being tested in trial NCT02476708?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), curcumin 1800mg (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02476708?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.